Intravenous immune globulin in chronic lymphocytic leukaemia.

Intravenous immune globulin in chronic lymphocytic leukaemia.

The most common complication of chronic lymphocytic leukaemia (CLL) is infection, which occurs mainly in advanced stages of disease or in those patients with hypogammaglobulinaemia. Intravenous immune globulin (IVIG) has been shown to be a useful prophylactic therapy against infections in such patie...

Full description

Bibliographic Details
Main Authors:	Gamm, H, Huber, C, Chapel, H, Lee, M, Ries, F, Dicato, M
Format:	Conference item
Published:	1994

Similar Items

Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review.
by: Dicato, M, et al.
Published: (1991)

Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes.
by: Chapel, H, et al.
Published: (1994)

Treatment of neonatal sepsis with intravenous immune globulin.
by: Brocklehurst, P, et al.
Published: (2011)

Predictors of infection in chronic lymphocytic leukaemia (CLL).
by: Griffiths, H, et al.
Published: (1992)

Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia.
by: Gamm, H, et al.
Published: (1988)

Immunoglobulin replacement in chronic lymphocytic leukaemia.
by: Bunch, C
Published: (1988)

MicroRNA expression in chronic lymphocytic leukaemia.
by: Lawrie, C, et al.
Published: (2009)

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
by: Oscier, D, et al.
Published: (2012)

The study of DNA methylation anomalies in chronic lymphocytic leukaemia
by: Roy, NBA
Published: (2011)

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
by: Parker, H, et al.
Published: (2016)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)
by: Binet, J, et al.
Published: (1998)

Progressive multifocal leukoencephalopathy as the presenting feature of chronic lymphocytic leukaemia.
by: Bruce, DR, et al.
Published: (2014)

Diminished thyroxine-binding globulin in pubertal diabetic children.
by: Connors, M, et al.
Published: (1996)

Intravenous immunoglobulin therapy.
by: Chapel, H
Published: (1996)

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
by: Lander, Eric Steven
Published: (2017)

Characterisation of the mutational landscape of chronic lymphocytic leukaemia using genome-wide approaches
by: Alsolami, R
Published: (2017)

Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis (Protocol)
by: Skoetz, N, et al.
Published: (2016)

Chronic neutrophilic leukaemia.
by: Gan, G.G., et al.
Published: (2007)

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
by: Hale, G, et al.
Published: (2004)

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
by: Catovsky, D, et al.
Published: (1998)

Targeted Gene Profiling Identifies Differential Genetic Make-up Depending On Chronic Lymphocytic Leukaemia Subtype
by: Burns, A, et al.
Published: (2012)

Targeted Gene Profiling Identifies Differential Genetic Make-up Depending On Chronic Lymphocytic Leukaemia Subtype
by: Burns, A, et al.
Published: (2012)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

Home intravenous immunoglobulin therapy.
by: Chapel, H, et al.
Published: (1988)

Hepatitis C and intravenous immunoglobulin - Concluding remarks
by: Chapel, H
Published: (1996)

Patients’ preferences for genomic diagnostic testing in chronic lymphocytic leukaemia: a discrete choice experiment
by: Buchanan, J, et al.
Published: (2016)

Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication.
by: Evans, J, et al.
Published: (2012)

Prognostic models for newly‐diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta‐analysis
by: Kreuzberger, N, et al.
Published: (2020)

Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
by: Steurer, M, et al.
Published: (2006)

Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.
by: Bass, E, et al.
Published: (1993)

The significance of deletion architecture, ATM mutational status and genomic complexity in 11q deleted Chronic Lymphocytic Leukaemia
by: Rose-Zerilli, M, et al.
Published: (2012)

Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution
by: Kasar, S., et al.
Published: (2017)

Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme.
by: Chowdhury, O, et al.
Published: (2011)

SAMHD1, A Putative Tumour Suppressor, Is Recurrently Mutated in Chronic Lymphocytic Leukaemia, and Is Associated with Poor Risk Features
by: Clifford, R, et al.
Published: (2012)

Intravenous immunoglobulin and hepatitis C virus: the British episode.
by: Healey, C, et al.
Published: (1996)

Effective interactions and colloidal stability of bovine γ-globulin in solution
by: Da Vela, S, et al.
Published: (2017)

Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.
by: Bosanquet, A, et al.
Published: (2009)

Conservation within cytotoxic T lymphocyte epitopes in hepatitis C virus in chronic infection.
by: Christie, J, et al.
Published: (1997)

Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia.
by: Rees-Unwin, K, et al.
Published: (2010)

Using genomic information to guide ibrutinib treatment decisions in chronic lymphocytic leukaemia: a cost-effectiveness analysis
by: Buchanan, J, et al.
Published: (2017)